Immunotherapy in non-small cell lung cancer harbouring driver mutations

•The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered and improved the therapeutic landscape of non-small cell lung cancer (NSCLC).•ICIs confer a durable response in a subset of patients; however, their therapeutic role in oncogene-driven NSCLC remains unclear, as the vast majority of trials was conducted without patients harbouring established oncogenic mutations.•The...